AVTX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

0.00

-100%

-1.443

-81.85%

-1.610

+28.8%

-1.505

-21.61%

Estimates Revision

The market is revising No Change the revenue expectations for Avalo Therapeutics, Inc. (AVTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 14.30%.

EPS Estimates for FY2025

Revise Upward

+24.8%

In Past 3 Month

Stock Price

Go Up

+14.30%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast AVTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTX is 37.00 USD with a low forecast of 25.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

25.00

Averages

37.00

High

48.00

Current: 0.000

Low

25.00

Averages

37.00

High

48.00

Mizuho

Joseph Catanzaro

Outperform

initiated

$39

2025-12-17

Reason

Mizuho

Joseph Catanzaro

Price Target

$39

2025-12-17

initiated

Outperform

Reason

Mizuho analyst Joseph Catanzaro initiated coverage of Avalo Therapeutics with an Outperform rating and $39 price target. The firm believes the company's lead program AVTX-009 is well positioned for a positive Phase II readout in hidradenitis suppurativa in mid-2026. It projects $1B in risk-adjusted 2035 worldwide sales for AVTX-009 and expects positive Phase II data to drive share outperformance.

Oppenheimer

Outperform

maintain

$35

2025-09-15

Reason

Oppenheimer

Price Target

$35

2025-09-15

maintain

Outperform

Reason

Oppenheimer recommends investors to be buyers of Avalo Therapeutics in anticipation of the presentation of lutikizumab's open-label Phase 2 data in about 40 treatment-naive hidradenitis suppurativa patients late this week. The firm, which forecasts \"strong results for luti\" at the EADV conference given its substantial benefit previously shown in a difficult-to-treat, TNF-refractory disease population, would expect '009 - with its multiple advantages over luti - to show \"at least as good as, and potentially better, efficacy\" when LOTUS reads out in mid-2026, says the analyst. The firm has an Outperform rating and $35 price target on Avalo shares.

TD Cowen

Stacy Ku

Buy

initiated

2025-09-05

Reason

TD Cowen

Stacy Ku

Price Target

2025-09-05

initiated

Buy

Reason

TD Cowen analyst Stacy Ku initiated coverage of Avalo Therapeutics with a Buy rating and no price target. The company's AVTX-009 is in a Phase II trial for hidradenitis suppurativa, with data expected in mid-2026, the analyst tells investors in a research note. The firm says key opinion leaders highlight the heterogeneous patient population and high unmet need. The leaders expect success with AVTX-009 with potential for a $1B-plus sales opportunity.

Cantor Fitzgerald

Prakhar Agrawal

Overweight

initiated

2025-08-15

Reason

Cantor Fitzgerald

Prakhar Agrawal

Price Target

2025-08-15

initiated

Overweight

Reason

Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of Avalo Therapeutics with an Overweight rating and no price target. Avalo is a clinical-stage biotech company focused on autoimmune diseases, the analyst tells investors in a research note. The firm says the company's lead drug AVTX-009 is an IL-1N2 antibody currently in a Phase 2 trial for hidradenitis suppurativa with a readout expected in mid-2026.

H.C. Wainwright

Mitchell Kapoor

initiated

$15

2025-06-02

Reason

H.C. Wainwright

Mitchell Kapoor

Price Target

$15

2025-06-02

initiated

Reason

H.C. Wainwright analyst Mitchell Kapoor assumed coverage of Avalo Therapeutics with a Buy rating and $15 price target. Avalo is a clinical-stage biotech company developing therapeutics for immunological diseases, the analyst tells investors in a research note. The firm says AVTX-009 is initially being developed to treat hidradenitis suppurativa, which is a large indication with an evolving standard-of-care regimen.

Jefferies

Kambiz Yazdi

Strong Buy

Initiates

$23

2025-03-25

Reason

Jefferies

Kambiz Yazdi

Price Target

$23

2025-03-25

Initiates

Strong Buy

Reason

Jefferies analyst Kambiz Yazdi initiated coverage of Avalo Therapeutics with a Buy rating and $23 price target. Avalo is a clinical stage biotechnology company focused on immunology and inflammation led by a veteran management team, the analyst tells investors in a research note. The firm says Avalo's lead asset AVTX-009 is an IL-1beta antibody in Phase 2 for the treatment of moderate to severe hidradenitis suppurativa with topline data expected in 2026. It thinks AVTX-009 is de-risked in part by lutikizumab data and that Avalo has an angle to show a differentiated profile.

Valuation Metrics

The current forward P/E ratio for Avalo Therapeutics Inc (AVTX.O) is -2.99, compared to its 5-year average forward P/E of -2.28. For a more detailed relative valuation and DCF analysis to assess Avalo Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.28

Current PE

-2.99

Overvalued PE

-0.30

Undervalued PE

-4.26

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

-76.31

Current PS

0.00

Overvalued PS

930.23

Undervalued PS

-1082.85

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 829.12% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

AVTX News & Events

Events Timeline

No data

News

4.0

2025-12-18Benzinga

Valvoline Analyst Starts Coverage Optimistically; Check Out Thursday's Top 5 Initiations

5.0

2025-11-17Newsfilter

Avalo Therapeutics Reveals Inducement Grants for New Hires in Accordance with Nasdaq Listing Rule 5635(c)(4)

9.0

2025-10-29Newsfilter

Avalo Therapeutics Completes Patient Enrollment in Phase 2 LOTUS Trial for AVTX-009 Targeting Hidradenitis Suppurativa Treatment

People Also Watch

Frequently Asked Questions

What is Avalo Therapeutics Inc (AVTX) stock price today?

The current price of AVTX is 17.11 USD — it has increased 1 % in the last trading day.

What is Avalo Therapeutics Inc (AVTX)'s business?

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).

What is the price predicton of AVTX Stock?

What is Avalo Therapeutics Inc (AVTX)'s revenue for the last quarter?

Avalo Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

What is Avalo Therapeutics Inc (AVTX)'s earnings per share (EPS) for the last quarter?

Avalo Therapeutics Inc. EPS for the last quarter amounts to -2.19 USD, decreased -22.61 % YoY.

What changes have occurred in the market's expectations for Avalo Therapeutics Inc (AVTX)'s fundamentals?

How many employees does Avalo Therapeutics Inc (AVTX). have?

Avalo Therapeutics Inc (AVTX) has 23 emplpoyees as of January 09 2026.

What is Avalo Therapeutics Inc (AVTX) market cap?

Today AVTX has the market capitalization of 310.27M USD.